Introduction: KRAS oncogene mutations ( MUT KRAS) drive resistance to EGFR inhibition by providing alternative signaling as demonstrated in colo-rectal cancer. In non-small cell lung cancer (NSCLC), the efficacy of treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) depends on activating EGFR mutations ( MUT EGFR). However, inhibition of EGFR may select resistant cells displaying alternative signaling, i.e., KRAS, or restoration of EGFR activity due to additional MUT EGFR, i.e., the c.2369C > T
INTRODUCTION
Activating mutations of epidermal growth factor receptor (
MUT EGFR) predict sensitivity to tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC). Despite a very high response rate (about 70%) to firstline treatment with the EGFR-TKIs (erlotinib, gefitinib or afatinib) in MUT EGFR NSCLC, tumors invariably progress after a median of 9-13 months from the beginning of treatment [1] [2] [3] .
The understanding of the molecular basis of acquired resistance to TKI [4] and its application to treatment monitoring may improve treatment management by discontinuing ineffective treatments and directing towards most appropriate second line options before clinical progression may occur. Indeed, EGFR signaling is maintained in most cases that develop secondary resistance [5] suggesting that additional molecular mechanisms can bypass EGFR-TKI inhibition reactivating the signaling pathway. Several mechanisms of acquired resistance to EGFR-TKI have been described after progression, including c.2369C > T (p.T790M) EGFR gatekeeper mutation (
EGFR, ~50% of patients) [6] , MET (5-15%) [7] or HER2 (12%) [8] amplifications, PIK3CA (4.1%) [9] or BRAF (1%) [10] mutations or transformation into small cell histology (3%) [11] .
NSCLC heterogeneity can drive the therapeutic decisions [12] ; therefore, tissue availability is increasingly recognized as a crucial issue. Unfortunately, the location of the tumor and the risk of complications are serious limitations to re-biopsies in NSCLC [13] . Alternatively, the detection of somatic mutations in cell-free tumor DNA (cftDNA) released in plasma could be instrumental for a better understanding of the genetic modifications driven by the selective pressure of drug treatments [14] .
Interestingly, approximately 15-25% of patients with NSCLC have KRAS mutations ( MUT KRAS), resulting in constitutive activation of KRAS signaling pathways. MUT KRAS is a negative predictor of benefit to anti-EGFR antibodies in colo-rectal cancer, while it seems to be a negative predictor of response to EGFR-TKIs in EGFR wild type ( WT EGFR) NSCLC patients [15] . In a previous study on a large collection of NSCLC tissues from patients with acquired resistance to EGFR-TKI, NRAS or KRAS mutations were not demonstrated [10] . Despite these negative results, we employed a sensitive ddPCR-based platform to investigate the presence of MUT KRAS alleles in plasma of patients resistant to EGFR-TKIs and we were able to demonstrate a potential role of MUT KRAS in acquired resistance to EGFR-TKI, besides the p.T790M
EGFR.
This finding reveals a potential new mechanism of resistance to EGFR-TKI and underscores the need of a periodic monitoring of somatic mutations of known oncogenes to deliver the best personalized treatment in a timely fashion.
RESULTS
The clinical characteristics of patients are reported in Table 1 
KRAS.
Fisher's extact test revealed that non-smoking habit and MUT KRAS were significantly associated (p = 0.026).
In 8 patients, paired re-biopsies and cftDNA were available. The 8 re-biopsies were performed in a different tumor site with respect to the initial diagnosis, the choice being dependent on several factors, i.e., anatomical accessibility, new or progressing lesions. KRAS as a mechanism of acquired resistance is 42% (14 patients). In terms of TTP and OS, there was no difference between these patients and the others (p = 0.19 and p = 0.13, respectively).
The concordance between tissue of re-biopsies (standard methods) and plasma (ddPCR), calculated by combining positive and negative results, was 62.5% and 37.5% for p.T790M
EGFR and
MUT KRAS, respectively (Table 3) . Moreover, three paired samples found positive for the p.T790M
EGFR on re-biopsies (standard methods) and on cftDNA (ddPCR), were negative by ddPCR on primary tissue ( Table 3) . BRAF and all the samples were found to be wild-type. Unfortunately, due to sample restriction, cftDNA was insufficient to perform the analysis of PI3K/Akt mutations. 
DISCUSSION
The present study demonstrates the presence of MUT KRAS in the cftDNA of a significant proportion of patients progressing after EGFR-TKI treatment. In addition to this, the present study provides evidence that sensitizing MUT EGFR and MUT KRAS can coexist after the selective pressure of EGFR-TKI treatment.
p.T790M EGFR determines acquired resistance by increasing the affinity of EGFR to ATP [16, 17] . p.T790M EGFR has been described in re-biopsies of 50-63% of tumors progressing under EGFR-TKI treatment [4, 11] and in the cftDNA at a frequency similar to our study . Because drugs active on p.T790M EGFR, such as AZD9291 and rociletinib [21, 22] , are under clinical study and will be available soon in the clinical practice, the identification of this molecular marker is of utmost clinical relevance.
In our study, EGFR. To our knowledge, a mechanism of resistance depending on activating MUT EGFR has not been previously reported; however, this cohort is too small to draw any conclusion.
MUT EGFR and MUT KRAS are mutually exclusive in primary NSCLC and only anecdotal case reports described their coexistence [23, 24] .
MUT KRAS occurs in approximately 20% of NSCLC cases at diagnosis, more frequently in Caucasian population, adenocarcinomas, males and current smokers [25, 26] . About 90% of KRAS mutations occur in exon 2 (codon 12 and 13), while exon 3 (codon 61) is less frequently involved [26, 27] ; in never-smokers with lung adenocarcinoma, MUT KRAS is more frequently a transition (G to A) compared to transversion in current smokers [25] . Colo-rectal cancer cells with MUT KRAS treated with anti-EGFR monoclonal antibodies are able to escape growth inhibition by several mechanisms, including MUT RAS [28] . While the role of MUT KRAS in primary resistance to EGFR-TKIs in molecularly unselected NSCLC is quite well established [29, 30] , its development and role in acquired resistance to EGFR-TKIs in MUT EGFR patients has not been explored in detail. In a previous work on a large collection of NSCLC tissues from patients with acquired EGFR-TKI resistance,
MUT NRAS or MUT KRAS were not demonstrated [10] . However, comparison with the present results is not possible because detailed information were not provided neither on the timing of sampling with respect of development of TKI resistance nor on the type of tissue analysed. Therefore, we addressed this issue and a sensitive ddPCR-based platform was employed to investigate the presence of MUT KRAS alleles besides the well-known p.T790M
EGFR. Due to its high sensitivity, ddPCR is able to identify small amounts of MUT KRAS and many methodological issues need to be addressed prospectically, particularly the threshold level of both MUT KRAS and p.T790M EGFR to be considered clinically relevant. However, a mechanism of drug resistance does not necessarily reflect biologic aggressiveness and the lack of difference in OS between KRAS wild-type and mutated patients it is therefore not surprising. The numeric dimension of the cell clone bearing MUT KRAS should be taken into consideration as well. Nevertheless, despite the low proportion of smokers in our cohort, the high prevalence of MUT KRAS could support its role of as mechanism of acquired resistance.
Eight patients underwent re-biopsy after tumor progression during EGFR-TKI, allowing a comparison between tissue and cftDNA. The detection of mutations in cftDNA but not in re-biopsy, using both standard methods and ddPCR, could suggest the presence of heterogeneity within metastatic sites or the lower performance of ddPCR in the presence of paraffin. Nevertheless, the detection of mutations in both plasma and tissue by ddPCR, but not by standard methods, could be due to the higher sensitivity of ddPCR analysis. Two patients, initially diagnosed WT KRAS by standard method, were re-analysed by ddPCR and were found MUT KRAS in the primary biopsy, suggesting that the MUT KRAS clone co-existed with activating MUT EGFR since the beginning, as also demonstrated in previous reports [23, 24] . In these patients, MUT KRAS cannot strictly be considered a mechanisms of resistance but it could be possible that EGFR-TKI treatment may have favored the expansion of MUT KRAS-positive clones. However, conclusions cannot be drawn as pre-treatment cftDNA was not available. MUT KRAS appeared before the initiation of TKI as a mechanism of resistance to previuos therapy. This hypotesis is weakened by the evidence that patients given second or further lines of therapy showed TTP and OS similar to patients treated in first line, although a mechanism of resistance does not necessarily affect survival. The presence of MUT KRAS has been recently reported using next generation sequencing analysis of tumor re-biopsies after progression under EGFR-TKI treatment [31] , similarly to colo-rectal cancer treated with EGFR antibodies [32, 33] . It remains to be determined if the presence of p.T790M
EGFR and
MUT KRAS coexist in the same tumor cell or arise in different subclones.
Targeting MUT KRAS proteins is still a challenge [34, 35] . Theoretically, combined treatment with KRAS and EGFR inhibitors can be administered to patients to prevent MUT KRAS-dependent resistance or restore sensitivity to EGFR-TKIs, as recently demonstrated co-targeting EGFR and MEK [36] . To date, p.T790M EGFR remains the most important predictor of efficacy of third generation EGFR-TKIs. Moreover, it was found that the coexistence of both activating MUT EGFR and MUT KRAS was not necessarily a negative predictor for EGFR-TKI therapy [23] . With these evidences in mind, all patients with p.T790M EGFR should receive third generation EGFR-TKI, even in the presence of MUT KRAS. Theoretically, it is possible that MUT KRAS identify a less responsive subgroup of patients but this hypothesis should be validated by monitoring patients prospectically during secondline therapy. Beside p.T790M
MUT KRAS, other mechanisms of acquired resistance not evaluated in our study have been described in tumor re-biopsies after EGFR-TKI progression, including actionable mutations of MET [7] , HER2 [8] , PIK3CA [9] or transformation into small cell histology (3%) [11] .
In conclusion, despite the small number of patients involved, the retrospective analysis and the low rate of re-biopsies, our results confirm the importance of cftDNA analysis for the monitoring of secondary mutations associated with EGFR-TKI resistance in NSCLC and underline the role of a highly sensitive approach, i. MUT EGFR needs to be further elucidated at the molecular level and encourages the development of inhibitors MUT KRAS for optimal treatment of patients. 
MATERIALS AND METHODS

Study population
presence; "-": absence of mutation; NA: sample not available; std: standard sequencing approach.
submitted and approved by the Ethics Committee of Pisa University Hospital and conducted in accordance to the principles of the Declaration of Helsinki; all patients gave their signed informed consent before blood collection and cftDNA analysis.
Plasma collection and cftDNA extraction
Six ml of blood were collected in EDTA and centrifuged at 4°C for 10 min at 3000 rpm within two hours after blood drawing. Plasma samples were stored at −80°C until analysis. cftDNA was extracted using a QIAmp Circulating nucleic acid Kit (Qiagen ® , Valencia, CA, USA) from 1 to 3 ml of plasma following the manufacturer's protocol and the DNA was eluted in 100 μl of buffer.
Analysis of cftDNA
The investigational part of this study included the assessment of codons 12, 13 (p.G13D) and 61 EGFR was assessed on pairwise cftDNA and tissue DNA of 8 patients who underwent re-biopsy for diagnostic purposes. DNA was extracted from formalin-fixed paraffin-embedded biopsies using the QIAmp DNA Mini Kit (Qiagen 
Data analysis
TTP and OS were calculated following standard procedures and survival curves were generated by the SPSS statistical software (version 16).
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